(Q44626945)

4 December 2017

title

Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz (English)

1 reference

4 December 2017

1 reference

1 reference

https://api.crossref.org/works/10.1097/00002030-200311070-00016

23 March 2024

3

David A. Katzenstein

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14571193

23 March 2024

author name string

Nicholas Hellmann

4

1 reference

4 December 2017

Lee Bacheler

5

1 reference

4 December 2017

ACTG 364 Study Team

7

1 reference

4 December 2017

Ronald J. Bosch

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14571193

23 March 2024

Gerald F. Downey

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14571193

23 March 2024

Mary A. Albrecht

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14571193

23 March 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

4 December 2017

7 November 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14571193

23 March 2024

1 reference

4 December 2017

volume

17

1 reference

4 December 2017

issue

16

1 reference

4 December 2017

page(s)

2395-2396

1 reference

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates

4 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/00002030-200311070-00016

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis

23 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/00002030-200311070-00016

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection

23 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/00002030-200311070-00016

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial

23 March 2024

4

1 reference

https://api.crossref.org/works/10.1097/00002030-200311070-00016

Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy

23 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/00002030-200311070-00016

23 March 2024

Identifiers

1 reference

4 December 2017

1 reference